Jason Jacques’ tenure as Canada’s interim Parliamentary Budget Officer (PBO) has ended, and the Prime Minister’s Office has not yet named a successor. His stint in the top chair, which expired at 5 ...

One of my favourite lines from the 1993 movie Philadelphia is, “Explain this to me like I’m a six-year-old.” I’ve used that line often during my 30-plus years in the tax profession to encourage people ...

Centre Block and the Peace Tower are seen past a metal fence along the lawn of Parliament Hill, in Ottawa, on Thursday, Sept. 5, 2024. THE CANADIAN PRESS/Justin Tang A new report from Canada’s fiscal ...

The parliamentary budget officer said Thursday he expects the coming fall budget will reveal a sharp increase in Ottawa’s deficit that puts the government’s previous fiscal anchors in jeopardy. Ottawa ...

Interim parliamentary budget officer Jason Jacques is warning that the federal government’s fiscal standing is deteriorating to an alarming degree, and that the country’s public finances will be ...

There will not be a new permanent parliamentary budget officer when the budget is released this fall, the Prime Minister’s Office has confirmed. In an email, PMO spokesperson Audrey Champoux said the ...

A performance boost can be achieved with just a few clicks — without the need for traditional overclocking. AMD’s Precision Boost Overdrive (PBO) provides a simple way to enhance Ryzen CPU performance ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Charlene Rhinehart is a CPA , CFE, ...

The Parliamentary Budget Officer estimates the federal deficit will hit $46 billion in the 2024-2025 fiscal year because of better-than-expected revenues. The PBO expects the deficit to be $4.3 ...

Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304. An international, multicenter, prospective randomized trial ...

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.